Abstract
Background
Squamous cell carcinoma antigen (SCC-Ag) level and C-reactive protein (CRP) have been shown to be associated with tumor invasion, lymph node metastasis, staging and survival in patients with oral squamous cell carcinoma (OSCC). The purpose of the present study was to analyze the relationship between preoperative levels of both SCC-Ag and CRP, with clinicopathologic factors and prognosis in OSCC patients.
Methods
A retrospective study was performed on 142 OSCC patients between March 2008 and March 2011. Their serum SCC-Ag and CRP levels were measured preoperatively.
Results
SCC-Ag level of ≥2.0 ng/ml and CRP level ≥5.0 mg/L were significantly associated with pathologic tumor status (P < 0.001), pathologic nodal metastasis (P = 0.001), tumor depth (≥10 mm vs. <10 mm, P < 0.001), disease-free survival (P ≤ 0.001) and overall survival (P ≤ 0.001). The influence of SCC-Ag and CRP level on disease-free survival (hazard ratio 4.046, 95 % confidence interval 1.698–9.692) and overall survival (hazard ratio 3.655, 95 % confidence interval 1.464–9.130) still existed after adjusting for tumor status, lymph node metastasis and tumor cell differentiation.
Conclusions
Concurrent high levels of both preoperative SCC-Ag and CRP levels act as a predictor for lymph node metastasis, advanced tumor stage and tumor recurrence. It therefore has significant potential as a biomarker for risk stratification in OSCC.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1245%2Fs10434-012-2392-5/MediaObjects/10434_2012_2392_Fig1_HTML.gif)
Similar content being viewed by others
References
Taiwan Cancer Registry. 2007 annual report. http://crs.cph.ntu.edu.tw/.
Liao CT, Wang HM, Ng SH, et al. Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated with radical surgery with or without neck dissection in Taiwan. Oral Oncol. 2006;42:800–9.
O’Brien CJ, Traynor SJ, McNeil E, McMahon JD, Chaplin JM. The use of clinical criteria alone in the management of the clinically negative neck among patients with squamous cell carcinoma of the oral cavity and oropharynx. Arch Otolaryngol Head Neck Surg. 2000;126:360–5.
Lin WH, Chen IH, Wei FC, et al. Clinical significance of preoperative squamous cell carcinoma antigen in oral-cavity squamous cell carcinoma. Laryngoscope. 2011;121:971–7.
Chen HH, Chen IH, Liao CT, Wei FC, Lee LY, Huang SF. Preoperative circulating C-reactive protein levels predict pathological aggressiveness in oral squamous cell carcinoma: a retrospective clinical study. Clin Otolaryngol. 2011;36:147–53.
Söderlund K, Stål O, Skoog L, Rutqvist LE, Nordenskjöld B, Askmalm MS. Intact Mre11/Rad50/Nbs1 complex predicts good response to radiotherapy in early breast cancer. Int J Radiat Oncol Biol Phys. 2007;68:50–8.
Kato H, Tamai K, Morioka H, Nagai M, Nagaya T, Torigoe T. Tumor-antigen TA-4 in the detection of recurrence in cervical squamous cell carcinoma. Cancer. 1984;54:1544–6.
Kawaguchi H, Ohno S, Miyazaki M, et al. CYFRA 21–1 determination in patients with esophageal squamous cell carcinoma: clinical utility for detection of recurrences. Cancer. 2000;89:1413–7.
Margolis ML, Hyzy JB, Schenken LL, Schepart BS. Serum tumor markers in non-small cell lung cancer. A comparative analysis. Cancer. 1994;73:605–9.
Pectasides D, Bafaloucos D, Antoniou F, et al. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19–9 for monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol. 1996;19:271–7.
Petrelli NJ, Shaw N, Bhargava A, et al. Squamous cell carcinoma antigen as a marker for squamous cell carcinoma of the anal canal. J Clin Oncol. 1988;6:782–5.
Eibling DE, Johnson JT, Wagner RL, Su S. SCC-RIA in the diagnosis of squamous cell carcinoma of the head and neck. Laryngoscope. 1989;99:117–24.
Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27:2217–24.
Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002;4:250–5.
McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, McArdle CS. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer. 2001;41:64–9.
Suh SY, Ahn HY. A prospective study on C-reactive protein as a prognostic factor for survival time of terminally ill cancer patients. Support Care Cancer. 2007;15:613–20.
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–45.
Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7.
Gunter MJ, Stolzenberg-Solomon R, Cross AJ, et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res. 2006;66:2483–7.
Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, editors. AJCC cancer staging manual. 6th ed. New York: Springer-Verlag; 2002.
Huang SF, Kang CJ, Lin CY, et al. Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer. 2008;112:1066–75.
Liao CT, Chang JT, Wang HM, et al. Analysis of risk factors of predictive local tumor control in oral cavity cancer. Ann Surg Oncol. 2008;15:915–22.
Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977, 40:1621–8.
Suminami Y, Nawata S, Kato H. Biological role of SCC antigen. Tumour Biol. 1998;19:488–93.
Takeda A, Kajiya A, Iwasawa A, Nakamura Y, Hibino T. Aberrant expression of serpin squamous cell carcinoma antigen 2 in human tumor tissues and cell lines: evidence of protection from tumor necrosis factor–mediated apoptosis. Biol Chem. 2002;383:1231–6.
Sueoka K, Nawata S, Nakagawa T, et al. Tumor-associated serpin, squamous cell carcinoma antigen stimulates matrix metalloproteinase-9 production in cervical squamous cell carcinoma cell lines. Int J Oncol. 2005;27:1345–53.
Brioschi PA, Bischof P, Delafosse C, Krauer F. Squamous-cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma. Int J Cancer. 1991;47:376–9.
Meier W, Eiermann W, Stieber P, Schneider A, Fateh-Moghadam A, Hepp H. Experiences with SCC antigen, a new tumor marker for cervical carcinoma. Eur J Cancer Clin Oncol. 1989;25:1555–9.
Neunteufel W, Tatra G, Bieglmayer C. Serum squamous cell carcinoma antigen levels in women with neoplasms of the lower genital tract and in healthy controls. Arch Gynecol Obstet. 1989;246:243–50.
Ngan HY, Chan SY, Wong LC, Choy DT, Ma HK. Serum squamous cell carcinoma antigen in the monitoring of radiotherapy treatment response in carcinoma of the cervix. Gynecol Oncol. 1990;37:260–3.
Scambia G, Panici PB, Baiocchi G, et al. The value of squamous cell carcinoma antigen in patients with locally advanced cervical cancer undergoing neoadjuvant chemotherapy. Am J Obstet Gynecol. 1991;164:631–6.
Senekjian EK, Young JM, Weiser PA, Spencer CE, Magic SE, Herbst AL. An evaluation of squamous cell carcinoma antigen in patients with cervical squamous cell carcinoma. Am J Obstet Gynecol. 1987;157:433–9.
Kimura Y, Fujieda S, Takabayashi T, Tanaka T, Sugimoto C, Saito H. Conventional tumor markers are prognostic indicators in patients with head and neck squamous cell carcinoma. Cancer Lett. 2000;155:163–8.
Lachowicz MA, Hassmann-Poznanska E, Kozlowski MD, Rzewnicki I. Squamous cell carcinoma antigen in patients with cancer of the larynx. Clin Otolaryngol Allied Sci. 1999;24:270–3.
Lara PC, Cuyas JM. The role of squamous cell carcinoma antigen in the management of laryngeal and hypopharyngeal cancer. Cancer. 1995;76:758–64.
Molina R, Torres MD, Moragas M, et al. Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. Tumour Biol. 1996;17:81–9.
Yasumatsu R, Nakashima T, Azuma K, et al. SCCA1 expression in T-lymphocytes peripheral to cancer cells is associated with the elevation of serum SCC antigen in squamous cell carcinoma of the tongue. Cancer Lett. 2001;167:205–13.
Krimmel M, Hoffmann J, Krimmel C, Cornelius CP, Schwenzer N. Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer. J Craniomaxillofac Surg. 1998;26:243–8.
Baron JA. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res. 2003;37:1–24.
Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J. 2009;32:471–82.
Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90.
Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2004;279:48487–90.
McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003;90:215–9.
Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006;94:1568–71.
Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856–64.
Heikkila K, Ebrahim S, Rumley A, Lowe G, Lawlor DA. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women’s Heart and Health Study. Cancer Epidemiol Biomarkers Prev. 2007;16:1155–9.
Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20:15–26.
McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol Int. 2006;77:127–9.
Gallo O, Gori AM, Attanasio M, et al. Interleukin-6 and acute-phase proteins in head and neck cancer. Eur Arch Otorhinolaryngol. 1995;252:159–62.
Jablonska E, Piotrowski L, Grabowska Z. Serum Levels of IL-1β, IL-6, TNF-α, sTNF-RI and CRP in patients with oral cavity cancer. Pathol Oncol Res. 1997;3:126–9.
Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45:912–4.
Kruse AL, Luebbers HT, Gratz KW. C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head Neck Oncol 2010;2:21.
Acknowledgment
This study was supported by grants CMRPG340381, CMRPG360701, CMRPG360851, CMRPG371511, and CMRPG3A0281 from the Chang Gung Memorial Hospital, NSC99-2314-B-182A-036-MY3 from the National Science Council, and DOH99-TD-C-111-006 from Department of Health, Department Executive Yuan, Taiwan.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
![](http://media.springernature.com/full/springer-static/esm/art%3A10.1245%2Fs10434-012-2392-5/MediaObjects/10434_2012_2392_MOESM1_ESM.jpg)
10434_2012_2392_MOESM1_ESM.jpg
Figure S1. Survival curves in 142 OSCC patients related to the preoperative CRP level. a The lower CRP group (<5.0 mg/L) showed significantly better DFS compared to the higher CRP level group (≥5.0 mg/L) (P < 0.001). b The lower CRP group showed significantly better OS compared to the higher CRP level group (P = 0.008). Supplementary material 1 (JPEG 938 kb)
![](http://media.springernature.com/full/springer-static/esm/art%3A10.1245%2Fs10434-012-2392-5/MediaObjects/10434_2012_2392_MOESM2_ESM.jpg)
10434_2012_2392_MOESM2_ESM.jpg
Figure S2. Survival curves in 142 OSCC patients related to the preoperative SCC-Ag level. a The lower SCC-Ag level group (<2.0 ng/ml) showed significantly better DFS compared to the higher SCC-Ag level group (≥2.0 ng/ml) (P = 0.001). b The lower SCC-Ag level group showed significantly better OS compared to the higher SCC-Ag level group (P = 0.018).Supplementary material 2 (JPEG 1009 kb)
![](http://media.springernature.com/full/springer-static/esm/art%3A10.1245%2Fs10434-012-2392-5/MediaObjects/10434_2012_2392_MOESM3_ESM.jpg)
10434_2012_2392_MOESM3_ESM.jpg
Figure S3. Scatter plot of CRP level versus SCC-Ag level (Pearson’s correlation = 0.891, P = 0.001). Supplementary material 4 (JPEG 23 kb)
Rights and permissions
About this article
Cite this article
Huang, SF., Wei, FC., Liao, CT. et al. Risk Stratification in Oral Cavity Squamous Cell Carcinoma by Preoperative CRP and SCC Antigen Levels. Ann Surg Oncol 19, 3856–3864 (2012). https://doi.org/10.1245/s10434-012-2392-5
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-012-2392-5